PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected Elizabeth M. Jaffee, MD, as their President-Elect for 2017-2018. She will officially become President-Elect at the AACR Annual Meeting 2017, to be held in Washington, April 1-5, and will assume the presidency in April 2018 at the Annual Meeting.
Jaffee is deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore; associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins; the Dana and Albert “Cubby” Broccoli professor of oncology; professor of pathology at the Johns Hopkins University School of Medicine; active staff in oncology at the Johns Hopkins Hospital; associate director for translational research, co-director of gastrointestinal cancer and diseases program, and co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care; and member of the faculty, Graduate Programs in Immunology, Cellular and Molecular Medicine, and Pharmacology, at the Johns Hopkins University School of Medicine.
Jaffee is an internationally recognized expert in cancer immunology, with specific expertise in preclinical and early clinical development of immunotherapies for breast and pancreatic cancers.
As AACR President-Elect, Jaffee will work with the Board of Directors and the AACR membership, which includes more than 37,000 members in 108 countries, to further the association’s mission to prevent and cure all cancers through research, education, communication, and collaboration.
“I am honored to serve the world’s first and largest professional organization dedicated to cancer research,” said Jaffee. “The AACR has fostered extensive collaboration among cancer researchers, helps to propel the careers of young scientists, and provides peer review for scores of cancer discoveries. Cancer research is accelerating at a fast pace, with notable advances in immunotherapy over just a few years. The AACR is at the forefront of keeping the scientific community abreast of these discoveries.”
“Dr. Jaffee is an esteemed physician-scientist whose pioneering work in cancer immunology and immunotherapy has had an enormous impact on the discovery and development of new and effective cancer treatments,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “She is also a distinguished, highly effective leader in cancer policy at the national level, and her work in this area has been deeply appreciated by the whole cancer community. We are delighted that Dr. Jaffee has been elected to serve as the 2017-2018 President-Elect of the AACR, for her expertise and vision will be invaluable as we work to carry out the important initiatives of the AACR’s Vision 2020 Strategic Plan.”
Jaffee is chair (2016-present) and member (2013-present) of the National Cancer Advisory Board for the National Cancer Institute (NCI) and co-chair of the NCI Blue Ribbon Panel for the National Cancer Moonshot Initiative (2016-present).
An active member of the AACR, Jaffee was elected to the Board of Directors (2013-2016). Her contributions to the AACR have been vast and far-reaching. She is serving as a member of the Organizing Committee of the AACR-LACOG Translational Cancer Medicine Conference in Brazil (2017), and other posts include co-chair (2015, 2017) and member (2006) of the Annual Meeting Program Committee; member of the NextGen Transformative Grants Scientific Review Committee (2015-2017); member of the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Organizing Committee (2015-2016); member of the Publications Committee (2014-2017); member of the Cancer Today Editorial Advisory Board (2014-present); chair (2012-2014) and member (2011, 2012) of the Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee; deputy editor of the AACR journal Cancer Immunology Research (2012-2015); chair (2012-2013) and member (2009-present) of the Cancer Immunology Working Group; member of the AACR-Princess Takamatsu Memorial Lectureship Award Selection Committee (2012); and co-chair of the Special Conferences “Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances” (2012) and “Tumor Immunology: Basic and Clinical Advances” (2010).
She has also been a member of the AACR Team Science Award Selection Committee (2011-2012, 2015-2017); member of the Tumor Microenvironment Working Group (2009-present); member of the Pancreatic Cancer Research Grants Scientific Review Committee (2009-2010); member of the AACR-Gertrude B. Elion Cancer Research Award Scientific Review Committee (2009); faculty for the Scientist↔Survivor Program at the Annual Meeting (2009); member of the Science Education Committee (2008-2011); co-chair of the Mentored Grants and Research Fellowships Committee (2008); faculty of the educational workshop “Methods in Clinical Cancer Research” (2008, 2009); member of the Annual Meeting Education Committee (2007, 2017); member of the Kirk A. Landon AACR Prize for Basic Cancer Research Selection Committee (2006); member of the Clinical and Translational Cancer Research Committee (2005-2008); faculty of the AACR Educational Workshop “Molecular Biology in Clinical Oncology” (2005); member of the Science Policy and Legislative Affairs Committee (2003-2014); associate editor of Cancer Research (2003-2005); member of the Clinical Cancer Research editorial board (2003-2005); member of the Women in Cancer Research Council; member of the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship Award Selection Committee (2002, 2007); and a member of the Molecular Cancer Therapeutics editorial board (2001-2004).
Jaffee is the leader of the Stand Up To Cancer (SU2C)-Lustgarten Foundation Dream Team: Transforming Pancreatic Cancer to a Treatable Disease. The AACR is the Scientific Partner of SU2C.
Jaffee has received many honors and awards. She was recognized with the AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research (2015), the Johns Hopkins University Office of Women in Science and Medicine Vice Dean’s Award (2012), the Spore Program Investigator of the Year from the NCI (2006), the Director’s Award for Outstanding Teaching from the Johns Hopkins University School of Medicine (1998, 1999, 2001), a Career Development Award from the National Kidney Foundation (1992), and the Physician-Scientist Award from the National Institutes of Health (1992).
Additionally, Jaffee has been a member of the International Society for Biological Therapy of Cancer’s board of directors (2008-2011) and the NCI’s board of scientific counselors (2005-2008).
Jaffee’s previously held positions are: deputy director of the Institute for Translational and Clinical Research at Johns Hopkins University School of Medicine (2007-2015); medical director of the Johns Hopkins Oncology Center, Cell Processing and Gene Therapy Facility (1992-2014); co-director of immunology (2006-2011) and chair of the Clinical Research Committee (2004-2005) at the Sidney Kimmel Comprehensive Cancer Center; associate professor of pathology (1999-2002), associate professor of oncology (1997-2002), and assistant professor of oncology (1992-1997) at Johns Hopkins University School of Medicine.
Jaffee graduated magna cum laude from Brandeis University in Waltham, Massachusetts, and received her medical degree from New York Medical College in Valhalla. For her postdoctoral training, Jaffee was a senior clinical fellow in oncology at the Johns Hopkins Hospital (1989-1992); senior clinical/research fellow in oncology at the Johns Hopkins University School of Medicine (1989-1992); and research fellow (1988-1989), and intern and resident (1985-1988) in the Department of Medicine at the University of Pittsburgh’s Presbyterian-University Hospital. She joined the faculty at Johns Hopkins in 1992.
Follow the AACR Annual Meeting 2017 on Twitter: #AACR17